Outlook Therapeutics, Inc. (OTLK)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
What's happening with OTLK?
Powered by Yahoo ScoutOutlook Therapeutics is building its commercial organization around LYTENAVA after securing U.S. approval for wet age-related macular degeneration. The company targets U.S. patient access before the end of 2026, while recent financing provides launch capital but creates dilution and funding risks. The most recent completed trading day ended up 0.20% on November 6, including regular-session and after-hours trading.
- Previous Close
0.4391 - Open
0.4210 - Bid 0.4090 x 500
- Ask 0.5525 x 200
- Day's Range
0.4200 - 0.4398 - 52 Week Range
0.1610 - 2.5380 - Volume
1,636,434 - Avg. Volume
9,868,387 - Market Cap (intraday)
106.241M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date (est.) Dec 18, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
5.03 - Zacks Rating Bullish
Recent News
View MorePerformance Overview
Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (current)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-143.17%
-
Return on Equity (ttm)
--
-
Revenue (ttm)
-1.16M
-
Net Income Avi to Common (ttm)
-61.12M
-
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
-
Total Cash (mrq)
11.24M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
-37.36M
